Verbatim response from ChatGPT
Short version
- Wegovy (Novo Nordisk) is the FDA‑approved, manufacturer‑made semaglutide product for weight management (label dose up to 2.4 mg weekly). It has known formulation, tested purity, validated manufacturing (GMP), clinical-trial evidence for safety and weight loss, an approved pen device, and manufacturer patient support.
- “Compounded semaglutide” is made by a compounding pharmacy from an active ingredient and mixed into a formulation on a prescription basis. It may contain the same active molecule but is not FDA‑approved as a finished drug product; quality, potency, sterility, excipients, stability, dosing concentration, and devices can vary.
Key differences (what actually matters)
- Regulatory status and evidence: Wegovy = FDA‑approved for chronic weight management with robust clinical-trial data. Compounded = not FDA‑approved; usually no large trials proving safety/efficacy of that specific preparation or dose.
- Manufacturing quality control: Wegovy is produced under strict GMP with lot testing. Compounded products depend on the pharmacy’s processes; standards vary.
- Purity and potency: Wegovy comes with guaranteed potency and formulation. Compounded products can vary unless the pharmacy provides batch testing / certificate of analysis (COA).
- Sterility and contamination risk: Wegovy is packaged and sterilized per manufacturer standards. Compounds carry higher risk if aseptic technique or sterile testing are insufficient.
- Formulation and excipients: Wegovy has a defined formulation and approved pen device. Compounds may use different solvents, concentrations, or supply in vials or syringes — raising risk of dosing errors or different stability.
- Dosing convenience and devices: Wegovy is prefilled in pens with clear dose increments and patient instructions. Many compounded versions come in vials or differently configured syringes and may require dose-splitting or extra handling.
- Legal/insurance/coverage: Wegovy may be covered (or have manufacturer assistance programs). Compounded semaglutide is usually out‑of‑pocket and often not covered by insurance.
- Safety monitoring / liability: Adverse events from Wegovy are well characterized; with a compounded product, it’s harder to know if an event is related to impurity, dose error, or the active drug.
When a compounded product might be considered
- If Wegovy is unavailable or unaffordable and you have a prescriber who thinks semaglutide is appropriate, some patients use a compound as a lower‑cost alternative. That choice carries more uncertainty and risk and should be made only after discussing with your clinician.
If you consider a compounded product: checklist for safety
- Use a reputable, accredited compounding pharmacy (look for PCAB accreditation and compliance with USP <797>/<795> standards).
- Ask for a current certificate of analysis (COA) for the batch and for sterility testing (if sterile injectable).
- Ask where the active pharmaceutical ingredient (API) came from and for documentation of its quality.
- Confirm exact concentration, dosing instructions, beyond‑use date, storage conditions, and whether the pharmacy tests potency over time.
- Prefer syringes/pens that minimize patient handling and dosing errors; get training on drawing/measuring doses.
- Keep copies of lot numbers and report adverse events.
Practical recommendation
- For safety, predictability, and proven benefit, Wegovy (Novo Nordisk) is the preferred choice. Novo Nordisk also offers patient support and savings programs that can sometimes reduce cost.
- If you must use compounded semaglutide, choose a PCAB‑accredited compounding pharmacy, require COAs and sterility/potency documentation, and coordinate closely with your prescriber for monitoring.
If you want, I can:
- Summarize the steps to verify a compounding pharmacy’s credentials,
- Provide wording you can use to ask a compounding pharmacy for COAs and sterility documentation, or
- Help compare cost options and manufacturer patient-assistance resources for Wegovy. Which would you like?